Clinical pharmacodynamic factors in docetaxel toxicity

[1]  A. Sparreboom,et al.  Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect , 2007, Cancer Chemotherapy and Pharmacology.

[2]  F. Goldwasser,et al.  Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms , 2006, Clinical pharmacology and therapeutics.

[3]  J. Verweij,et al.  Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.

[4]  J. Verweij,et al.  Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Ohmatsu,et al.  Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Dalenc,et al.  Dexamethasone as a probe for docetaxel clearance , 2004, Cancer Chemotherapy and Pharmacology.

[7]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Verweij,et al.  Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Lewis B. Sheiner,et al.  A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[10]  S. Urien,et al.  Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein , 2004, Investigational New Drugs.

[11]  L B Sheiner,et al.  Estimating population kinetics. , 1982, Critical reviews in biomedical engineering.